For research and educational purposes only. Not medical advice.
LGD-4033 Reference
Educational, not medical advice reference for LGD-4033: SARM, Recovery; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
Phase 1/2 healthy-men trials reported lean-mass increase and HPTA suppression. Long-term outcome data, body-composition-trial efficacy data in healthy adults, and any FDA-approval program are absent.
- Categories
- SARM, Recovery
- Aliases
- Ligandrol, Anabolicum, VK5211, Non-steroidal SARM
- Evidence posture
- human — FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 anabolic agents at all times, in and out of competition. No FDA-approved drug label and no human clinical efficacy program for body-composition use. Some US states have placed LGD-4033 under Schedule III; possession without a prescription may be a state-level controlled-substance offense.
- Regulatory status
- No FDA-approved LGD-4033 drug label. FDA has issued explicit consumer warnings against SARMs sold in bodybuilding products. WADA prohibits LGD-4033 under category S1.2 anabolic agents at all times. Several US states have placed LGD-4033 under state-level Schedule III provisions; federal scheduling status varies, and possession outside an approved indication may be a state-level controlled-substance offense.
- Content review status
- research reference